LDN193189 information

LDN193189
Names
	Preferred IUPAC name 4-{6-[4-(Piperazin-1-yl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl}quinoline
Identifiers
CAS Number	1062368-24-4 ;
3D model (JSmol)	Interactive image;
PubChem CID	25195294;
UNII	W69H5YQU9O ;
CompTox Dashboard (EPA)	DTXSID30147553 ;
	InChI InChI=1S/C25H22N6/c1-2-4-24-22(3-1)21(9-10-27-24)23-16-29-31-17-19(15-28-25(23)31)18-5-7-20(8-6-18)30-13-11-26-12-14-30/h1-10,15-17,26H,11-14H2 Key: CDOVNWNANFFLFJ-UHFFFAOYSA-N;
	SMILES C1(C2=C3N=CC(C4=CC=C(N5CCNCC5)C=C4)=CN3N=C2)=CC=NC6=CC=CC=C16;
Properties
Chemical formula	C25H22N6
Molar mass	406.493 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

LDN193189 is a chemical compound used in the study of bone morphogenetic protein signalling through the ALK2, ALK3 and ALK6 receptors.^[1] It has been researched for the treatment of fibrodysplasia ossificans progressiva.^[2]

^ Cuny GD, Yu PB, Laha JK, Xing X, Liu JF, Lai CS, Deng DY, Sachidanandan C, Bloch KD, Peterson RT. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4388-92. doi:10.1016/j.bmcl.2008.06.052 PMID 18621530
^ Williams E, Bullock AN. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2. Bone. 2018 Apr;109:251-258. doi:10.1016/j.bone.2017.09.004 PMID 28918311

[1] Cuny GD, Yu PB, Laha JK, Xing X, Liu JF, Lai CS, Deng DY, Sachidanandan C, Bloch KD, Peterson RT. Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors. Bioorg Med Chem Lett. 2008 Aug 1;18(15):4388-92. doi:10.1016/j.bmcl.2008.06.052 PMID 18621530

[2] Williams E, Bullock AN. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2. Bone. 2018 Apr;109:251-258. doi:10.1016/j.bone.2017.09.004 PMID 28918311